Relmada Therapeutics, Inc. RLMD Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s other commercial liabilities?
- Relmada Therapeutics, Inc. (RLMD) reported other commercial liabilities of $7.16M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s other commercial liabilities changed year-over-year?
- Relmada Therapeutics, Inc.'s other commercial liabilities increased by 80.5% year-over-year, from $3.97M to $7.16M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s other commercial liabilities?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s other commercial liabilities has grown at a 2.7% compound annual growth rate (CAGR), from $4.26M to $4.86M.